In a recent announcement by Pfizer, it was claimed that a phase 2/3 trial showed its covid 19 vaccines are safe as well as generating robust antibody response in children aged between 5 to 11 years. Pfizer is the first ever to provide such results in terms of the Covid-19 vaccine for this particular age group, although the data has not yet been peer-reviewed or published. Pfizer has said that it is soon planning to submit a request for emergency use authorization to the US Food and Drug Administration. Which, FDA officials have communicated that once the report is submitted; the agency can authorize a vaccine for younger children within weeks. This trial of vaccine by Pfizer included 2,268 participants aged between 5 to 11 years, and a two-dose vaccine regimen was given and administered 21 days apart.